Cidel Asset Management Inc. Has $360,000 Stock Position in Becton, Dickinson and Company $BDX

Cidel Asset Management Inc. grew its stake in shares of Becton, Dickinson and Company (NYSE:BDX) by 9.6% during the 2nd quarter, Holdings Channel.com reports. The firm owned 2,092 shares of the medical instruments supplier’s stock after buying an additional 184 shares during the quarter. Cidel Asset Management Inc.’s holdings in Becton, Dickinson and Company were worth $360,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in BDX. Saudi Central Bank acquired a new stake in shares of Becton, Dickinson and Company in the 1st quarter worth about $26,000. Smallwood Wealth Investment Management LLC acquired a new stake in shares of Becton, Dickinson and Company in the 1st quarter worth about $27,000. Alpine Bank Wealth Management acquired a new stake in shares of Becton, Dickinson and Company in the 1st quarter worth about $29,000. Cornerstone Planning Group LLC raised its holdings in shares of Becton, Dickinson and Company by 341.4% in the 1st quarter. Cornerstone Planning Group LLC now owns 128 shares of the medical instruments supplier’s stock worth $29,000 after acquiring an additional 99 shares during the last quarter. Finally, Kelly Lawrence W & Associates Inc. CA acquired a new stake in shares of Becton, Dickinson and Company in the 1st quarter worth about $31,000. Institutional investors and hedge funds own 86.97% of the company’s stock.

Insider Buying and Selling at Becton, Dickinson and Company

In other news, Director Claire Fraser sold 917 shares of the stock in a transaction that occurred on Wednesday, September 10th. The shares were sold at an average price of $187.50, for a total transaction of $171,937.50. Following the completion of the transaction, the director directly owned 22,226 shares of the company’s stock, valued at $4,167,375. This represents a 3.96% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Over the last ninety days, insiders have sold 1,838 shares of company stock worth $348,392. 0.36% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on the stock. Morgan Stanley upped their target price on shares of Becton, Dickinson and Company from $196.00 to $197.00 and gave the stock an “overweight” rating in a report on Monday, August 11th. Wall Street Zen raised shares of Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research report on Saturday, August 9th. Argus upped their price objective on shares of Becton, Dickinson and Company from $220.00 to $230.00 in a research report on Monday, September 15th. Wells Fargo & Company upped their price objective on shares of Becton, Dickinson and Company from $172.00 to $184.00 and gave the stock an “equal weight” rating in a research report on Friday, August 8th. Finally, Royal Bank Of Canada reaffirmed a “sector perform” rating and issued a $211.00 price objective on shares of Becton, Dickinson and Company in a research report on Thursday. Three research analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $205.40.

Becton, Dickinson and Company Trading Up 2.1%

Shares of BDX stock opened at $189.20 on Monday. Becton, Dickinson and Company has a 52-week low of $163.33 and a 52-week high of $251.99. The company has a 50-day simple moving average of $190.60 and a two-hundred day simple moving average of $184.37. The company has a market capitalization of $54.23 billion, a price-to-earnings ratio of 34.03, a PEG ratio of 1.48 and a beta of 0.25. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.62 and a current ratio of 1.10.

Becton, Dickinson and Company (NYSE:BDX) last released its earnings results on Thursday, April 14th. The medical instruments supplier reported $4.10 earnings per share for the quarter. Becton, Dickinson and Company had a net margin of 7.51% and a return on equity of 16.23%. The firm had revenue of $5.32 billion during the quarter. Research analysts anticipate that Becton, Dickinson and Company will post 14.43 EPS for the current fiscal year.

Becton, Dickinson and Company Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Tuesday, September 30th. Stockholders of record on Monday, September 8th were given a dividend of $1.04 per share. This represents a $4.16 dividend on an annualized basis and a dividend yield of 2.2%. The ex-dividend date of this dividend was Monday, September 8th. Becton, Dickinson and Company’s dividend payout ratio is currently 74.82%.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.